Navigation Links
Ranexa(R) Significantly Reduces Ischemia in Women in MERLIN TIMI-36 Study
Date:11/6/2007

ORLANDO, Fla., Nov. 6 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that an analysis of data from 2,291 women who participated in the MERLIN TIMI-36 study showed a 29 percent reduction in the relative risk of recurrent ischemia in women receiving Ranexa(R) (ranolazine extended-release tablets) compared to placebo (p=0.002) after 12 months. No difference in symptomatic documented arrhythmias was observed in women between the ranolazine and placebo groups.

The data were presented today by Dr. Jessica Mega of the TIMI Study Group at the American Heart Association Scientific Sessions in Orlando, Florida.

"Women were very well represented in the MERLIN TIMI-36 study and these data provide important additional confirmation of the safety and efficacy we have seen with Ranexa in other clinical trials and in commercial use," said Louis G. Lange, CV Therapeutics chairman and chief executive officer.

According to the American Heart Association, cardiovascular disease is the leading cause of death among American women.

In accordance with a special protocol assessment agreement between the U.S. Food and Drug Administration (FDA) and CV Therapeutics, the Company believes that data from the MERLIN TIMI-36 study could support expansion of the existing Ranexa indication to first line angina. In September 2007, the Company submitted a supplemental new drug application to the FDA seeking a new indication for first line angina and a significant reduction in cautionary language.

Ranexa is currently indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine,
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Ranexa(R) Significantly Reduces Incidence of CV Death, MI or Recurrent Ischemia in MERLIN TIMI-36 Patients With Elevated BNP
2. Prophylactic cranial irradiation in small cell lung cancer significantly increases survival
3. Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision; Believes Offer Significantly Undervalues Company
4. Study shows adverse drug events reported to the FDA have significantly increased
5. Rehabilitation significantly underused after heart attack and bypass surgery
6. Promising Phase 3 trial results show biologic therapy ustekinumab significantly improved psoriasis
7. National Domestic Violence Hotline Unveils 10-Year Blueprint to Significantly Reduce Domestic Violence in America
8. New Study Shows Arthritis Significantly Limits Millions of Americans Ability to Work
9. World Bank Group Report on Malaria in Africa Highlights Progress Towards Goal of Significantly Reducing Malaria Deaths
10. Psychiatrists, parents significantly differ in ADHD, psychiatric comorbidities perceptions
11. Phase II Study Shows that Nitazoxanide Significantly Improves Response to Standard of Care in Patients with Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... (PRWEB) December 26, 2014 The ... Analysis to 2023” focuses on the current treatment ... in the colorectal cancer market. Stivarga is a ... colon or rectal cancer. Boehringer Ingelheim is developing ... the treatment of refractory CRC in the US, ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online ... its collection of discounted prom dresses, most of which ... spokesman of the company, the promotion is valid until ... to expand the UK market. , The prom dresses ... lengths, and styles: A-line strapless, empire strapless chiffon, one ...
(Date:12/25/2014)... FL (PRWEB) December 25, 2014 When head ... find themselves in a frenzy to get rid of it ... But families in Coral Gables now have the solution right ... second salon clinic location, Lice Troopers provides full spectrum head ... the Coral Gable area, including Sunset, Key Biscayne, Brickell, Coconut ...
(Date:12/25/2014)... WEDNESDAY, Dec. 24, 2014 (HealthDay News) -- Among early ... treatment, less than half of one percent will eventually ... new analysis reveals. The finding comes from a ... between 1998 and 2007, and it suggests that the ... double what experts had previously thought. "The frequency ...
(Date:12/25/2014)... Plugin creators from Pixel Film Studios have ... business presentation tool made specifically for Final Cut ... tool, users can now display their stats and facts ... Studios. “ProFire 5k gives users a multiple options to ... a presentation” , Pixel Film Studios takes the heat ...
Breaking Medicine News(10 mins):Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2
... BD (Becton, Dickinson and Company) (NYSE: BDX ), a global medical technology company, ... , Bank of America and Merrill Lynch 2009 ... 8:40 a.m. EDT, Bernstein,s ... 2009, 9:00 a.m. EDT, ...
... (Nasdaq: WCRX ) announced today that one ... ("Mayne") have filed a second lawsuit against Mylan Pharmaceuticals ... for the District of New Jersey for infringement of ... covers DORYX, a tetracycline-class oral antibiotic. The lawsuit ...
... better understood after taking hands-on approach , , FRIDAY, May ... specific training and tools can help young doctors do ... patients. , Seniors face added challenges with prescriptions, ... one time. Avoiding their greater susceptibility to side effects ...
... Award Honoring the Work of Oncology , NursesSAN ANTONIO, ... CURE magazine,s 2009 Extraordinary Healer Award for Oncology ... during a special reception at the Oncology Nursing Society,s ... patients and caregivers submitted nominations. The winner, Christine ...
... continues; Obama urges calm; global cases total 331 in 11 ... -- The number of confirmed swine flu cases in the ... health officials reported on Friday. , "That,s up eight states ... the U.S. Centers for Disease Control and Prevention,s science ...
... May 1 As the world sits on the ... attempting to reduce the ranks of personnel most skilled ... representing more than 20,000 Registered Nurses in 89 bargaining ... hospitals to reopen contracts regarding wages. In the ...
Cached Medicine News:Health News:Warner Chilcott Files New Lawsuit for Infringement of DORYX(R) Patent 2Health News:Warner Chilcott Files New Lawsuit for Infringement of DORYX(R) Patent 3Health News:Prescription Training Puts Docs in Shoes of Older Patients 2Health News:Winner of 2009 CURE Magazine Extraordinary Healer Award Announced 2Health News:Winner of 2009 CURE Magazine Extraordinary Healer Award Announced 3Health News:Swine Flu Infections Now at 141 in 19 U.S. States 2Health News:Swine Flu Infections Now at 141 in 19 U.S. States 3Health News:Swine Flu Infections Now at 141 in 19 U.S. States 4Health News:Swine Flu Infections Now at 141 in 19 U.S. States 5Health News:Swine Flu Infections Now at 141 in 19 U.S. States 6Health News:Swine Flu Infections Now at 141 in 19 U.S. States 7Health News:Swine Flu Infections Now at 141 in 19 U.S. States 8Health News:Swine Flu Infections Now at 141 in 19 U.S. States 9Health News:Hospital Staffing Cuts - Pragmatic, Panic or Carefully Planned? 2Health News:Hospital Staffing Cuts - Pragmatic, Panic or Carefully Planned? 3
(Date:12/24/2014)...   Synageva BioPharma Corp. (NASDAQ: ... products for rare disorders, today announced validation by ... Authorization Application (MAA) for sebelipase alfa for LAL ... for accelerated assessment, which has the potential to ... The MAA, and the Biologics License Application ...
(Date:12/24/2014)... CHENGDU, China , Dec. 23, 2014 /PRNewswire/ ... a pharmaceutical company that specializes in patented biopharmaceutical, ... active pharmaceutical ingredients (API) today announced that the ... for its Good Manufacturing Practice (GMP) certificate of ... & Drug Administration,s (CFDA). The public notice period ...
(Date:12/22/2014)... 22, 2014  CytoSorbents Corporation (OTCQB:CTSOD), a critical ... purification technology to help fight deadly inflammation in ... worldwide, today announced the appointment of Dr. ... its Senior Vice President of Clinical Development, effective ... Di Russo is an accomplished pediatric cardiothoracic ...
Breaking Medicine Technology:Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
... Neuro Kinetics, Inc. (NKI) ( www.neuro-kinetics.com ), manufacturers of ... vestibular and neurological conditions, said today that it co-presented ... conference meeting in Scottsdale, Arizona. The research ... clinical testing that can be conducted with its medical ...
... 2011 IRIDEX Corporation (Nasdaq: IRIX ) today reported ... improved financial results for the fourth quarter ended January 1, 2011. ... per share, up from $0.5 million or $0.05 per diluted share ... to $12.2 million in the 2010 fourth quarter, up 6% from ...
Cached Medicine Technology:Neuro Kinetics Presenting New Balance & Dizziness Research at American Balance Society Conference 2IRIDEX Reports Strong Growth and Profits in 2010 Fourth Quarter 2IRIDEX Reports Strong Growth and Profits in 2010 Fourth Quarter 3IRIDEX Reports Strong Growth and Profits in 2010 Fourth Quarter 4IRIDEX Reports Strong Growth and Profits in 2010 Fourth Quarter 5